American Society of Hematology, Blood Advances, 17(4), p. 4086-4090, 2020
DOI: 10.1182/bloodadvances.2020002060
Full text: Download
Key Points VTE developed in 11% of lymphoma patients after CAR T-cell therapy and was managed safely with anticoagulation. Coagulation abnormalities after CAR T-cell therapy occur but do not commonly lead to bleeding events.